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Dear Editor,
We read with interest the review of clinical practice guide-
lines for antifungal therapy in paediatric haematology and
oncology published in January’s edition [1]. Morgan and col-
leagues describe the importance of fungal infections in chil-
dren, particularly those with haematological malignancies and
undergoing allogeneic stem cell transplantation. As highlight-
ed, significant variation in practice has been previously
demonstrated.
In reviewing published clinical practice guidelines,
Morgan et al. conducted an appropriate electronic review of
the literature and included adult guidelines given that paediat-
ric guidelines could be embedded. The authors note that the
quality of the included guidelines was variable with only two
meeting the pre-study definition of GOOD quality using the
AGREE II assessment. [2].
We were pleased that a previous version of the Australasian
paediatric antifungal guidelines (2007) was included [3], yet
note that the comprehensive update of paediatric and adult
Australian and New Zealand antifungal guidelines were omit-
ted [4–12]. Published in December 2014, these expanded
guidelines included manuscripts on prophylaxis, empiric and
diagnostic-driven antifungal strategies, treatment of yeast, in-
vasive mould and Pneumocystis jirovecii infection. They also
provided guidance on optimising antifungal drug delivery and
therapeutic drug monitoring. Comprehensive systematic re-
views were undertaken and writing groups inclusive of infec-
tious diseases physicians, haematologists, hospital pharma-
cists, microbiologists and infection prevention consultants
[11]. A paediatrician with expertise in managing fungal infec-
tions was included in every writing group. All recommenda-
tions were assessed using the grading system endorsed by the
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and distributed for wider comment to key interest groups.
Conflicts of interest were declared by all contributors. These
guidelines now form the basis for national antibiotic and an-
tifungal recommendations.
We write to highlight to readers of Supportive Care in
Cancer, the additional high-quality, peer-reviewed antifungal
prophylaxis and treatment clinical practice guidelines that
may assist prescribers in managing individual patients and
hospital and health-care facilities in developing institutional
recommendations.
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